Linked Life Data

10090953

Source:http://linkedlifedata.com/resource/pubmed/id/10090953

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10090953rdf:typepubmed:Citationlld:pubmed
pubmed-article:10090953lifeskim:mentionsumls-concept:C0011306lld:lifeskim
pubmed-article:10090953lifeskim:mentionsumls-concept:C0021013lld:lifeskim
pubmed-article:10090953lifeskim:mentionsumls-concept:C0042196lld:lifeskim
pubmed-article:10090953lifeskim:mentionsumls-concept:C0439859lld:lifeskim
pubmed-article:10090953lifeskim:mentionsumls-concept:C0439064lld:lifeskim
pubmed-article:10090953lifeskim:mentionsumls-concept:C0015730lld:lifeskim
pubmed-article:10090953lifeskim:mentionsumls-concept:C0242602lld:lifeskim
pubmed-article:10090953pubmed:issue7lld:pubmed
pubmed-article:10090953pubmed:dateCreated1999-4-19lld:pubmed
pubmed-article:10090953pubmed:abstractTextThe idiotype (Id) determinant on the multiple myeloma (MM) protein can be regarded as a tumor-specific marker. Immunotherapy directed at the MM Id may stem the progression of this disease. We report here on the first 12 MM patients treated at our institution with high-dose therapy and peripheral blood stem cell transplantation (PBSCT) followed by Id immunizations. MM patients received PBSCT to eradicate the majority of the disease. PBSCT produced a complete response in 2 patients, a partial response in 9 patients and stable disease in 1 patient. Three to 7 months after high-dose therapy, patients received a series of monthly immunizations that consisted of two intravenous infusions of Id-pulsed autologous dendritic cells (DC) followed by five subcutaneous boosts of Id/keyhole limpet hemocyanin (KLH) administered with adjuvant. Between 1 and 11 x 10(6) DC were obtained by leukapheresis in all patients even after PBSCT. The administration of Id-pulsed DC and Id/KLH vaccines were well tolerated with patients experiencing only minor and transient side effects. Two of 12 patients developed an Id-specific, cellular proliferative immune response and one of three patients studied developed a transient but Id-specific cytotoxic T-cell (CTL) response. Eleven of the 12 patients generated strong KLH-specific cellular proliferative immune responses showing the patients' immunocompetence at the time of vaccination. The two patients who developed a cellular Id-specific immune response remain in complete remission. Of the 12 treated patients, 9 are currently alive after autologous transplantation with a minimum follow-up of 16 months, 2 patients died because of recurrent MM and 1 patient succumbed to acute leukemia. These studies show that patients make strong anti-KLH responses despite recent high-dose therapy and that DC-based Id vaccination is feasible after PBSCT and can induce Id-specific T-cell responses. Further vaccine development is necessary to increase the proportion of patients that make Id-specific immune responses. The clinical benefits of Id vaccination in MM remain to be determined.lld:pubmed
pubmed-article:10090953pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10090953pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10090953pubmed:languageenglld:pubmed
pubmed-article:10090953pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10090953pubmed:citationSubsetAIMlld:pubmed
pubmed-article:10090953pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10090953pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10090953pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10090953pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10090953pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10090953pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10090953pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10090953pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10090953pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10090953pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10090953pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10090953pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10090953pubmed:statusMEDLINElld:pubmed
pubmed-article:10090953pubmed:monthAprlld:pubmed
pubmed-article:10090953pubmed:issn0006-4971lld:pubmed
pubmed-article:10090953pubmed:authorpubmed-author:LissEElld:pubmed
pubmed-article:10090953pubmed:authorpubmed-author:LevyRRlld:pubmed
pubmed-article:10090953pubmed:authorpubmed-author:BlumeK GKGlld:pubmed
pubmed-article:10090953pubmed:authorpubmed-author:EnglemanE GEGlld:pubmed
pubmed-article:10090953pubmed:authorpubmed-author:BenikeC JCJlld:pubmed
pubmed-article:10090953pubmed:authorpubmed-author:OkadaC YCYlld:pubmed
pubmed-article:10090953pubmed:authorpubmed-author:Stockerl-Gold...lld:pubmed
pubmed-article:10090953pubmed:authorpubmed-author:ReichardtV...lld:pubmed
pubmed-article:10090953pubmed:issnTypePrintlld:pubmed
pubmed-article:10090953pubmed:day1lld:pubmed
pubmed-article:10090953pubmed:volume93lld:pubmed
pubmed-article:10090953pubmed:ownerNLMlld:pubmed
pubmed-article:10090953pubmed:authorsCompleteYlld:pubmed
pubmed-article:10090953pubmed:pagination2411-9lld:pubmed
pubmed-article:10090953pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:10090953pubmed:meshHeadingpubmed-meshheading:10090953...lld:pubmed
pubmed-article:10090953pubmed:meshHeadingpubmed-meshheading:10090953...lld:pubmed
pubmed-article:10090953pubmed:meshHeadingpubmed-meshheading:10090953...lld:pubmed
pubmed-article:10090953pubmed:meshHeadingpubmed-meshheading:10090953...lld:pubmed
pubmed-article:10090953pubmed:meshHeadingpubmed-meshheading:10090953...lld:pubmed
pubmed-article:10090953pubmed:meshHeadingpubmed-meshheading:10090953...lld:pubmed
pubmed-article:10090953pubmed:meshHeadingpubmed-meshheading:10090953...lld:pubmed
pubmed-article:10090953pubmed:meshHeadingpubmed-meshheading:10090953...lld:pubmed
pubmed-article:10090953pubmed:meshHeadingpubmed-meshheading:10090953...lld:pubmed
pubmed-article:10090953pubmed:meshHeadingpubmed-meshheading:10090953...lld:pubmed
pubmed-article:10090953pubmed:meshHeadingpubmed-meshheading:10090953...lld:pubmed
pubmed-article:10090953pubmed:meshHeadingpubmed-meshheading:10090953...lld:pubmed
pubmed-article:10090953pubmed:meshHeadingpubmed-meshheading:10090953...lld:pubmed
pubmed-article:10090953pubmed:meshHeadingpubmed-meshheading:10090953...lld:pubmed
pubmed-article:10090953pubmed:meshHeadingpubmed-meshheading:10090953...lld:pubmed
pubmed-article:10090953pubmed:meshHeadingpubmed-meshheading:10090953...lld:pubmed
pubmed-article:10090953pubmed:meshHeadingpubmed-meshheading:10090953...lld:pubmed
pubmed-article:10090953pubmed:meshHeadingpubmed-meshheading:10090953...lld:pubmed
pubmed-article:10090953pubmed:meshHeadingpubmed-meshheading:10090953...lld:pubmed
pubmed-article:10090953pubmed:meshHeadingpubmed-meshheading:10090953...lld:pubmed
pubmed-article:10090953pubmed:meshHeadingpubmed-meshheading:10090953...lld:pubmed
pubmed-article:10090953pubmed:meshHeadingpubmed-meshheading:10090953...lld:pubmed
pubmed-article:10090953pubmed:meshHeadingpubmed-meshheading:10090953...lld:pubmed
pubmed-article:10090953pubmed:meshHeadingpubmed-meshheading:10090953...lld:pubmed
pubmed-article:10090953pubmed:meshHeadingpubmed-meshheading:10090953...lld:pubmed
pubmed-article:10090953pubmed:meshHeadingpubmed-meshheading:10090953...lld:pubmed
pubmed-article:10090953pubmed:meshHeadingpubmed-meshheading:10090953...lld:pubmed
pubmed-article:10090953pubmed:meshHeadingpubmed-meshheading:10090953...lld:pubmed
pubmed-article:10090953pubmed:meshHeadingpubmed-meshheading:10090953...lld:pubmed
pubmed-article:10090953pubmed:meshHeadingpubmed-meshheading:10090953...lld:pubmed
pubmed-article:10090953pubmed:meshHeadingpubmed-meshheading:10090953...lld:pubmed
pubmed-article:10090953pubmed:meshHeadingpubmed-meshheading:10090953...lld:pubmed
pubmed-article:10090953pubmed:year1999lld:pubmed
pubmed-article:10090953pubmed:articleTitleIdiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma--a feasibility study.lld:pubmed
pubmed-article:10090953pubmed:affiliationDivision of Oncology, Stanford Blood Center, Stanford University Medical Center, Stanford, CA, USA.lld:pubmed
pubmed-article:10090953pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10090953pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:10090953pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:10090953pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10090953lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10090953lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10090953lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10090953lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10090953lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10090953lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10090953lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10090953lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10090953lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10090953lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10090953lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10090953lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10090953lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10090953lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10090953lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10090953lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10090953lld:pubmed
More...